Nektar Therapeutics
NASDAQ:NKTRBiotechnology
-$1.24 today
- Market cap
- $987.44M
- Beta
- 1.15
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$6.39
Volume 0.71M
Average 1.00M
NKTR Operating Cash Flow
Cash generated by the company's core business operations during the period.
Nektar TherapeuticsNASDAQ: NKTR
Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Operating cash flow growth accelerates
Q2 FY2026 operating cash flow of $75.77M (cash outflow) rose 65.7% year over year, ahead of the +26.4% change in trailing-twelve-month operating cash flow. Sequentially, it rose 71.0% from the prior quarter. Over 3 fiscal years it compounded at -11.8% a year.
Context
- Operating cash flow amounted to 377.5% of revenue in FY2025, up 199.0 pp from a year earlier.
- Operating cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +65.7% holds above the trailing-twelve-month pace of +26.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (208.51M) USD
- Year-over-year change
- -18.7%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (208.51M) | -18.7% |
| FY2024 | 2024-12-31 | (175.71M) | +8.8% |
| FY2023 | 2023-12-31 | (192.61M) | +36.6% |
| FY2022 | 2022-12-31 | (304.01M) | +26.3% |
| FY2021 | 2021-12-31 | (412.66M) | — |
Operating Cash Flow vs competitors
How NKTR compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +26.4% is the 4th highest of 9, against a peer median of +18.9%.
- Operating cash flow amounts to 428.3% of revenue for NKTR, versus a peer median of 363.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $474M USD | +39.8% | — | 405.1% | |
| LTM Jun 2026 | $233.79M USD | +26.4% | -11.8% | 428.3% | |
| LTM Jun 2026 | $205.81M USD | +53.4% | — | 196.1% | |
| LTM Mar 2026 | €184.13M EUR | +15.3% | — | 493.7% | |
| LTM Mar 2026 | $170.57M USD | -34214.6% | -16.9% | 363.8% | |
| LTM Mar 2026 | $69.96M USD | +0.5% | -2.3% | 44.5% | |
| LTM Jun 2024 | $66.7M USD | — | -8.1% | 1027.7% | |
| FY2025 | €50.67M EUR | +634.8% | +38.3% | 1818.2% | |
| LTM Mar 2026 | $34.91M USD | +22.4% | +6.7% | — | |
| LTM Mar 2026 | $24.9M USD | -180.1% | -45.5% | 6.5% | |
| LTM Dec 2025 | $0 USD | — | — | 0.0% | |
| Peer median (excluding NKTR) | — | +18.9% | -5.2% | 363.8% | |
Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (523.84M) | (368.2M) | (276.06M) | (118.96M) | (164.08M) |
| Depreciation & Amortization | 14.15M | 13.03M | 7.82M | 4.39M | (4.49M) |
| Deferred Income Tax | 8.02M | 2.71M | (140K) | 0 | 0 |
| Stock-Based Compensation | 94.67M | 57.32M | 33.39M | 21.61M | 12.65M |
| Change in Working Capital | (23.08M) | 492K | (19.8M) | (6.24M) | (37.02M) |
| Accounts Receivables | 12.4M | 16.51M | 4.78M | (3.05M) | 0 |
| Inventory | (509K) | (3.4M) | 699K | 497K | 0 |
| Accounts Payables | (11.69M) | 3.1M | (2.88M) | 2.67M | (625K) |
| Other Working Capital | (23.27M) | (15.72M) | (22.39M) | (6.36M) | (36.39M) |
| Other Non-Cash Items | 17.41M | (9.36M) | 62.19M | (76.51M) | (15.58M) |
| Operating Cash Flow | (412.66M) | (304.01M) | (192.61M) | (175.71M) | (208.51M) |
| Capital Expenditures | (14.99M) | (5.68M) | (865K) | (1.47M) | (171K) |
| Acquisitions (Net) | (217.77M) | 13.2M | 0 | 65.39M | (697K) |
| Purchases of Investments | (960.69M) | (467.91M) | (511.7M) | (261.71M) | (285.01M) |
| Sales of Investments | 1.18B | 826.23M | 650.88M | 340.36M | 284.68M |
| Other Investing Activities | 217.77M | 0 | 1.25M | 0 | 0 |
| Investing Cash Flow | 202.78M | 365.84M | 139.56M | 142.57M | (1.2M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 33.24M | 758K | 30K | 30.12M | 180.57M |
| Common Stock Repurchased | 0 | 0 | 0 | (3M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3M | 750K | 0 | 15M | 0 |
| Financing Cash Flow | 36.24M | 1.51M | 30K | 42.12M | 180.57M |
| Effect of Forex Changes | (92K) | (327K) | 62K | (4K) | 6K |
| Net Change in Cash | (173.74M) | 63.01M | (52.95M) | 8.98M | (29.14M) |
| Free Cash Flow | (427.65M) | (309.68M) | (193.47M) | (177.18M) | (208.68M) |
Nektar Therapeutics
NASDAQ:NKTR
Intrinsic Alpha fair value
Locked
Current Price
$34.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.